Landiolol Hydrochloride Powder for Injection for Infusion (Rapiblyk®)

Rapiblyk® Powder for Injection for Infusion contains landiolol hydrochloride 300 mg, equivalent to 280 mg landiolol.

Indication:
Rapiblyk® is indicated in adults for: • Supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. • non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Rapiblyk® is not intended for use in chronic settings.